-
A413893-100mgInformationAZD8835 ia a novel mixed inhibitor ofPI3KαandPI3Kδwith IC50 of 6.2 nM and 5.7 nM, respectively, also with selectivity againstPI3Kβ(IC50=431 nM) andPI3Kγ(IC50=90 nM).TargetsPI3Kδ (Cell-based assay): PI3Kα (Cell-free assay): PI3Kγ
-
A413893-10mgInformationAZD8835 ia a novel mixed inhibitor ofPI3KαandPI3Kδwith IC50 of 6.2 nM and 5.7 nM, respectively, also with selectivity againstPI3Kβ(IC50=431 nM) andPI3Kγ(IC50=90 nM).TargetsPI3Kδ (Cell-based assay): PI3Kα (Cell-free assay): PI3Kγ
-
A413893-25mgInformationAZD8835 ia a novel mixed inhibitor ofPI3KαandPI3Kδwith IC50 of 6.2 nM and 5.7 nM, respectively, also with selectivity againstPI3Kβ(IC50=431 nM) andPI3Kγ(IC50=90 nM).TargetsPI3Kδ (Cell-based assay): PI3Kα (Cell-free assay): PI3Kγ
-
A413893-50mgInformationAZD8835 ia a novel mixed inhibitor ofPI3KαandPI3Kδwith IC50 of 6.2 nM and 5.7 nM, respectively, also with selectivity againstPI3Kβ(IC50=431 nM) andPI3Kγ(IC50=90 nM).TargetsPI3Kδ (Cell-based assay): PI3Kα (Cell-free assay): PI3Kγ
-
A413893-5mgInformationAZD8835 ia a novel mixed inhibitor ofPI3KαandPI3Kδwith IC50 of 6.2 nM and 5.7 nM, respectively, also with selectivity againstPI3Kβ(IC50=431 nM) andPI3Kγ(IC50=90 nM).TargetsPI3Kδ (Cell-based assay): PI3Kα (Cell-free assay): PI3Kγ
-
-
-
A129380-10mgAZD8931 is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt.A potent
-
A129380-1mgAZD8931 is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt.A potent
-
A129380-50mgAZD8931 is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt.A potent
-
A129380-5mgAZD8931 is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt.A potent
-
A607893-10mgAZD9056 hydrochloride is a selective orally active inhibitor of P2X7 which plays a significant role in inflammation and pain-causing diseases.